Brightlands Maastricht Health Campus
Oxfordlaan 55 6229 EV Maastricht, Nederland (Google Maps)
Cristal Therapeutics is a clinical stage company developing nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential.
The Company’s product candidates are based on its proprietary CriPec® platform, which enables the rationaldesign of customised nanomedicinesto target specific tissue, cells and intracellular components, and to have a defined duration at disease sites.
CriPec®based products have the potential to provide enhanced efficacy and reduced side effect profiles over current treatment options available in the clinic. The lead product, CPC634 (a CriPec entrapped version of the widely used chemotherapeutic docetaxel), is in clinical phase 2studies for the treatment of solid tumourswhere it has demonstrated a much improved safety profile and tumour targeting. Cristal Therapeutics is also applying its technology to other products in combination with biotech and pharma partners.
Cristal Therapeutics was founded in April 2011, as a spin-off of the Department of Pharmaceutics of Utrecht University by Cristianne Rijcken, PharmD PhD and Joost Holthuis PhD.The company is led by a management team of entrepreneurial life science executives and supported by an industry-experienced Supervisory Board and internationally renowned Scientific Board.
Go back to the overview of all companies at Brightlands Maastricht Health Campus